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Reply
We would like to thank Drs. MacFadyen and Chuen for their interest
in our study (1). They seem to conclude that our population-based
report advocates screening for all persons with dyspnea. Unfortu-
nately, the majority of the issues they raise are based on this false
assumption. We believe that it is necessary to await the results from
studies evaluating the cost-effectiveness before introducing pro–B-
type natriuretic peptide (proBNP) as a screening tool of all breathless
persons in the community. We agree that if one sought to examine
the cost-effectiveness of the natriuretic peptides in primary care, they
should include the additional information that is obtainable for the
general practitioner.
The aim of our study was to examine whether or not plasma
proBNP could be used in discriminating between cardiac and pulmo-
nary dysfunction in the general population with dyspnea. Our findings
that plasma proBNP is increased in left ventricular dilation, hyper-
trophy, systolic and diastolic dysfunction, but unaffected by pulmonary
dysfunction, should be viewed in this perspective. Drs. MacFadyen
and Chuen also point out that 48% of the population in our study
reported dyspnea without having an abnormal conventional echocar-
diogram or pulmonary function test. It is important to emphasize that
a normal conventional echocardiogram does not rule out cardiac
dysfunction. Most of these people (83%) were only complaining of
mild dyspnea. Compared with their nondyspneic counterparts, they
had a higher frequency of ischemic heart disease and risk factors for
ischemic heart disease. Conventional echocardiography does not
provide much information about longitudinal myocardial contractility,
which is impaired initially in ischemic heart disease. In fact, we
suspect that breathless persons with a high level of plasma proBNP
have a high risk of cardiac dysfunction, although they might have
normal conventional echocardiograms. Further research with more
advanced modalities (e.g., tissue Doppler imaging) within such groups
is needed.
Intraindividual and interindividual variability of plasma
proBNP should not be extrapolated from studies of BNP or
N-terminal proBNP. The interindividual variability is one of the
major reasons for the assay’s gray zone reported in our study,
whereas the intraindividual variability of the assay is small (2).
Regarding the ability to rule out parenchymal lung disease by
spirometry, pulse oxymetry, and clinical history, we agree that
additional information from computed tomography scans and lung
biopsy would have been interesting but obviously not possible in
this population study. Concerning the last issue of pulmonary
hypertension in parenchymal lung disease, we have previously
shown that plasma proBNP only increases at elevated mean
pulmonary artery pressures 50 mm Hg in patients with terminal
parenchymal lung disease (3).
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Plaque Burden,
Intravascular Ultrasound, and
Distal Embolization Phenomenon
Although embolization of atherothrombotic material during stent
deployment is probably ubiquitous, its causes and consequences
remain poorly characterized. In a recent issue of the Journal, both
Kawaguchi et al. (1) and Kawamoto et al. (2) suggested that vessels
most likely to sustain distal embolization could be identified using
virtual histology (VH) intravascular ultrasound (IVUS) to quantify
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